Literature DB >> 16825985

Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group.

Michal A Miller1, Kensuke Ohashi, Xiaoyan Zhu, Patrick McGrady, Wendy B London, Michael Hogarty, Anthony D Sandler.   

Abstract

Alterations in apoptotic mechanisms favoring cell survival may be vital for modifying tumor behavior. Survivin, an inhibitor of apoptosis, and caspase 8, a proapoptotic enzyme, are key players in cellular apoptotic mechanisms. We investigated whether the levels of survivin and caspase 8 and the ratio between these 2 apoptotic factors correlate with tumor biology and predicts outcome in patients with neuroblastoma. Survivin and caspase 8 levels were quantified in 38 primary tumor specimens and analyzed individually and in relation to each other. High survivin expression and high survivin:caspase 8 ratios were associated with MYCN amplification, unfavorable histology, and high-risk group of disease (P<0.0008). High survivin mRNA levels were associated with worse overall survival (P=0.02) although the median follow up was only 22.6 months with a range of 1 day to 3.3 years. Low caspase 8 expression was associated with stage 4 disease, high-risk group, MYCN amplification, and unfavorable histology. Although the survivin:caspase 8 ratio was associated with these risk factors, the ratio did not improve the predictive value of survivin alone in this small series. Quantifying multiple apoptotic genes in neuroblastoma may supplement current risk stratification. Moreover, categorizing aberrant apoptotic gene expression in neuroblastoma may translate into novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825985     DOI: 10.1097/01.mph.0000212937.00287.e5

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  9 in total

1.  Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.

Authors:  Ayman Samkari; Zachary A Cooper; Michael P Holloway; Jiebin Liu; Rachel A Altura
Journal:  Int J Biochem Mol Biol       Date:  2012-02-10

2.  Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Authors:  Joëlle Vermeulen; Katleen De Preter; Arlene Naranjo; Liesbeth Vercruysse; Nadine Van Roy; Jan Hellemans; Katrien Swerts; Sophie Bravo; Paola Scaruffi; Gian Paolo Tonini; Bruno De Bernardi; Rosa Noguera; Marta Piqueras; Adela Cañete; Victoria Castel; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jean Michon; Valérie Combaret; Matthias Fischer; André Oberthuer; Peter F Ambros; Klaus Beiske; Jean Bénard; Bárbara Marques; Hervé Rubie; Janice Kohler; Ulrike Pötschger; Ruth Ladenstein; Michael D Hogarty; Patrick McGrady; Wendy B London; Geneviève Laureys; Frank Speleman; Jo Vandesompele
Journal:  Lancet Oncol       Date:  2009-06-08       Impact factor: 41.316

3.  Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.

Authors:  Petra Obexer; Judith Hagenbuchner; Thomas Unterkircher; Nora Sachsenmaier; Christoph Seifarth; Günther Böck; Verena Porto; Kathrin Geiger; Michael Ausserlechner
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

4.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

5.  A 6-gene signature identifies four molecular subgroups of neuroblastoma.

Authors:  Frida Abel; Daniel Dalevi; Maria Nethander; Rebecka Jörnsten; Katleen De Preter; Joëlle Vermeulen; Raymond Stallings; Per Kogner; John Maris; Staffan Nilsson
Journal:  Cancer Cell Int       Date:  2011-04-14       Impact factor: 5.722

6.  The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.

Authors:  Susan K Peirce; Harry W Findley; Chengyu Prince; Anindya Dasgupta; Todd Cooper; Donald L Durden
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-24       Impact factor: 3.333

7.  Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.

Authors:  Judith Hagenbuchner; Martina Rupp; Christina Salvador; Bernhard Meister; Ursula Kiechl-Kohlendorfer; Thomas Müller; Kathrin Geiger; Consolato Sergi; Petra Obexer; Michael J Ausserlechner
Journal:  Oncotarget       Date:  2016-11-22

8.  How to target apoptosis signaling pathways for the treatment of pediatric cancers.

Authors:  Simone Fulda
Journal:  Front Oncol       Date:  2013-02-14       Impact factor: 6.244

9.  Apoptotic cell death in neuroblastoma.

Authors:  Yuanyuan Li; Akira Nakagawara
Journal:  Cells       Date:  2013-06-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.